Nano carriers for drug transport across the blood–brain barrier

Xinming Li, John Tsibouklis, Tingting Weng, Buning Zhang, Guoqiang Yin, Guangzhu Feng, Yingde Cui, Irina N. Savina, Lyuba I. Mikhalovska, Susan R. Sandeman, Carol A. Howel, Sergey V. Mikhalovsky

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

Effective therapy lies in achieving a therapeutic amount of drug to the proper site in the body and then maintaining the desired drug concentration for a sufficient time interval to be clinically effective for treatment. The blood–brain barrier (BBB) hinders most drugs from entering the central nervous system (CNS) from the blood stream, leading to the difficulty of delivering drugs to the brain via the circulatory system for the treatment, diagnosis and prevention of brain diseases. Several brain drug delivery approaches have been developed, such as intracerebral and intracerebroventricular administration, intranasal delivery and blood-to-brain delivery, as a result of transient BBB disruption induced by biological, chemical or physical stimuli such as zonula occludens toxin, mannitol, magnetic heating and ultrasound, but these approaches showed disadvantages of being dangerous, high cost and unsuitability for most brain diseases and drugs. The strategy of vector-mediated blood-to-brain delivery, which involves improving BBB permeability of the drug–carrier conjugate, can minimize side effects, such as being submicrometre objects that behave as a whole unit in terms of their transport and properties, nanomaterials, are promising carrier vehicles for direct drug transport across the intact BBB as a result of their potential to enter the brain capillary endothelial cells by means of normal endocytosis and transcytosis due to their small size, as well as their possibility of being functionalized with multiple copies of the drug molecule of interest. This review provids a concise discussion of nano carriers for drug transport across the intact BBB, various forms of nanomaterials including inorganic/solid lipid/polymeric nanoparticles, nanoemulsions, quantum dots, nanogels, liposomes, micelles, dendrimers, polymersomes and exosomes are critically evaluated, their mechanisms for drug transport across the BBB are reviewed, and the future directions of this area are fully discussed.

Original languageEnglish
Pages (from-to)17-28
Number of pages12
JournalJournal of Drug Targeting
Volume25
Issue number1
DOIs
Publication statusPublished - Jan 2 2017

Fingerprint

Drug Carriers
Pharmaceutical Preparations
Brain
Nanostructures
Brain Diseases
Central Nervous System Agents
Exosomes
Transcytosis
Dendrimers
Intranasal Administration
Quantum Dots
Micelles
Mannitol
Therapeutics
Cardiovascular System
Endocytosis
Liposomes
Nanoparticles
Heating
Permeability

Keywords

  • Blood–brain barrier
  • drug delivery
  • nanomaterials

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Li, X., Tsibouklis, J., Weng, T., Zhang, B., Yin, G., Feng, G., ... Mikhalovsky, S. V. (2017). Nano carriers for drug transport across the blood–brain barrier. Journal of Drug Targeting, 25(1), 17-28. https://doi.org/10.1080/1061186X.2016.1184272

Nano carriers for drug transport across the blood–brain barrier. / Li, Xinming; Tsibouklis, John; Weng, Tingting; Zhang, Buning; Yin, Guoqiang; Feng, Guangzhu; Cui, Yingde; Savina, Irina N.; Mikhalovska, Lyuba I.; Sandeman, Susan R.; Howel, Carol A.; Mikhalovsky, Sergey V.

In: Journal of Drug Targeting, Vol. 25, No. 1, 02.01.2017, p. 17-28.

Research output: Contribution to journalReview article

Li, X, Tsibouklis, J, Weng, T, Zhang, B, Yin, G, Feng, G, Cui, Y, Savina, IN, Mikhalovska, LI, Sandeman, SR, Howel, CA & Mikhalovsky, SV 2017, 'Nano carriers for drug transport across the blood–brain barrier', Journal of Drug Targeting, vol. 25, no. 1, pp. 17-28. https://doi.org/10.1080/1061186X.2016.1184272
Li, Xinming ; Tsibouklis, John ; Weng, Tingting ; Zhang, Buning ; Yin, Guoqiang ; Feng, Guangzhu ; Cui, Yingde ; Savina, Irina N. ; Mikhalovska, Lyuba I. ; Sandeman, Susan R. ; Howel, Carol A. ; Mikhalovsky, Sergey V. / Nano carriers for drug transport across the blood–brain barrier. In: Journal of Drug Targeting. 2017 ; Vol. 25, No. 1. pp. 17-28.
@article{9f910496c2154d8fbfc50ba34b16bf64,
title = "Nano carriers for drug transport across the blood–brain barrier",
abstract = "Effective therapy lies in achieving a therapeutic amount of drug to the proper site in the body and then maintaining the desired drug concentration for a sufficient time interval to be clinically effective for treatment. The blood–brain barrier (BBB) hinders most drugs from entering the central nervous system (CNS) from the blood stream, leading to the difficulty of delivering drugs to the brain via the circulatory system for the treatment, diagnosis and prevention of brain diseases. Several brain drug delivery approaches have been developed, such as intracerebral and intracerebroventricular administration, intranasal delivery and blood-to-brain delivery, as a result of transient BBB disruption induced by biological, chemical or physical stimuli such as zonula occludens toxin, mannitol, magnetic heating and ultrasound, but these approaches showed disadvantages of being dangerous, high cost and unsuitability for most brain diseases and drugs. The strategy of vector-mediated blood-to-brain delivery, which involves improving BBB permeability of the drug–carrier conjugate, can minimize side effects, such as being submicrometre objects that behave as a whole unit in terms of their transport and properties, nanomaterials, are promising carrier vehicles for direct drug transport across the intact BBB as a result of their potential to enter the brain capillary endothelial cells by means of normal endocytosis and transcytosis due to their small size, as well as their possibility of being functionalized with multiple copies of the drug molecule of interest. This review provids a concise discussion of nano carriers for drug transport across the intact BBB, various forms of nanomaterials including inorganic/solid lipid/polymeric nanoparticles, nanoemulsions, quantum dots, nanogels, liposomes, micelles, dendrimers, polymersomes and exosomes are critically evaluated, their mechanisms for drug transport across the BBB are reviewed, and the future directions of this area are fully discussed.",
keywords = "Blood–brain barrier, drug delivery, nanomaterials",
author = "Xinming Li and John Tsibouklis and Tingting Weng and Buning Zhang and Guoqiang Yin and Guangzhu Feng and Yingde Cui and Savina, {Irina N.} and Mikhalovska, {Lyuba I.} and Sandeman, {Susan R.} and Howel, {Carol A.} and Mikhalovsky, {Sergey V.}",
year = "2017",
month = "1",
day = "2",
doi = "10.1080/1061186X.2016.1184272",
language = "English",
volume = "25",
pages = "17--28",
journal = "Journal of Drug Targeting",
issn = "1061-186X",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Nano carriers for drug transport across the blood–brain barrier

AU - Li, Xinming

AU - Tsibouklis, John

AU - Weng, Tingting

AU - Zhang, Buning

AU - Yin, Guoqiang

AU - Feng, Guangzhu

AU - Cui, Yingde

AU - Savina, Irina N.

AU - Mikhalovska, Lyuba I.

AU - Sandeman, Susan R.

AU - Howel, Carol A.

AU - Mikhalovsky, Sergey V.

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Effective therapy lies in achieving a therapeutic amount of drug to the proper site in the body and then maintaining the desired drug concentration for a sufficient time interval to be clinically effective for treatment. The blood–brain barrier (BBB) hinders most drugs from entering the central nervous system (CNS) from the blood stream, leading to the difficulty of delivering drugs to the brain via the circulatory system for the treatment, diagnosis and prevention of brain diseases. Several brain drug delivery approaches have been developed, such as intracerebral and intracerebroventricular administration, intranasal delivery and blood-to-brain delivery, as a result of transient BBB disruption induced by biological, chemical or physical stimuli such as zonula occludens toxin, mannitol, magnetic heating and ultrasound, but these approaches showed disadvantages of being dangerous, high cost and unsuitability for most brain diseases and drugs. The strategy of vector-mediated blood-to-brain delivery, which involves improving BBB permeability of the drug–carrier conjugate, can minimize side effects, such as being submicrometre objects that behave as a whole unit in terms of their transport and properties, nanomaterials, are promising carrier vehicles for direct drug transport across the intact BBB as a result of their potential to enter the brain capillary endothelial cells by means of normal endocytosis and transcytosis due to their small size, as well as their possibility of being functionalized with multiple copies of the drug molecule of interest. This review provids a concise discussion of nano carriers for drug transport across the intact BBB, various forms of nanomaterials including inorganic/solid lipid/polymeric nanoparticles, nanoemulsions, quantum dots, nanogels, liposomes, micelles, dendrimers, polymersomes and exosomes are critically evaluated, their mechanisms for drug transport across the BBB are reviewed, and the future directions of this area are fully discussed.

AB - Effective therapy lies in achieving a therapeutic amount of drug to the proper site in the body and then maintaining the desired drug concentration for a sufficient time interval to be clinically effective for treatment. The blood–brain barrier (BBB) hinders most drugs from entering the central nervous system (CNS) from the blood stream, leading to the difficulty of delivering drugs to the brain via the circulatory system for the treatment, diagnosis and prevention of brain diseases. Several brain drug delivery approaches have been developed, such as intracerebral and intracerebroventricular administration, intranasal delivery and blood-to-brain delivery, as a result of transient BBB disruption induced by biological, chemical or physical stimuli such as zonula occludens toxin, mannitol, magnetic heating and ultrasound, but these approaches showed disadvantages of being dangerous, high cost and unsuitability for most brain diseases and drugs. The strategy of vector-mediated blood-to-brain delivery, which involves improving BBB permeability of the drug–carrier conjugate, can minimize side effects, such as being submicrometre objects that behave as a whole unit in terms of their transport and properties, nanomaterials, are promising carrier vehicles for direct drug transport across the intact BBB as a result of their potential to enter the brain capillary endothelial cells by means of normal endocytosis and transcytosis due to their small size, as well as their possibility of being functionalized with multiple copies of the drug molecule of interest. This review provids a concise discussion of nano carriers for drug transport across the intact BBB, various forms of nanomaterials including inorganic/solid lipid/polymeric nanoparticles, nanoemulsions, quantum dots, nanogels, liposomes, micelles, dendrimers, polymersomes and exosomes are critically evaluated, their mechanisms for drug transport across the BBB are reviewed, and the future directions of this area are fully discussed.

KW - Blood–brain barrier

KW - drug delivery

KW - nanomaterials

UR - http://www.scopus.com/inward/record.url?scp=85011983749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011983749&partnerID=8YFLogxK

U2 - 10.1080/1061186X.2016.1184272

DO - 10.1080/1061186X.2016.1184272

M3 - Review article

VL - 25

SP - 17

EP - 28

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1061-186X

IS - 1

ER -